Balaxi Pharmaceuticals Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Sources of funds

Owner's fund

Equity share capital

10.18

10.00

10.00

10.00

3.04

Share application money

10.30

-

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

71.63

47.91

33.25

18.11

0.48

Loan funds

Secured loans

10.75

-

-

-

-

Unsecured loans

-

1.93

3.51

-

-

Total

102.86

59.84

46.75

28.11

3.52

Uses of funds

Fixed assets

Gross block

8.41

2.45

0.78

0.19

0.01

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

0.52

0.25

0.09

0.01

-

Net block

7.89

2.20

0.69

0.19

0.01

Capital work-in-progress

2.83

0.57

-

-

-

Investments

19.54

19.61

19.54

0.10

-

Net current assets

Current assets, loans & advances

99.46

59.53

48.69

37.62

6.10

Less : current liabilities & provisions

26.87

22.07

22.17

9.79

2.59

Total net current assets

72.60

37.46

26.52

27.83

3.51

Miscellaneous expenses not written

-

-

-

-

-

Total

102.86

59.84

46.75

28.11

3.52

Notes:

Book value of unquoted investments

-

19.61

19.54

0.10

-

Market value of quoted investments

-

-

-

-

-

Contingent liabilities

-

-

-

-

-

Number of equity sharesoutstanding (Lacs)

101.81

100.00

100.00

100.00

30.40